
Neuren Pharmaceuticals Ltd
ASX:NEU

Intrinsic Value
The intrinsic value of one
NEU
stock under the Base Case scenario is
6.63
AUD.
Compared to the current market price of 10.53 AUD,
Neuren Pharmaceuticals Ltd
is
Overvalued by 37%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Neuren Pharmaceuticals Ltd
Fundamental Analysis

Regulatory uncertainty surrounding Neuren’s lead candidate trofinetide—particularly in complex neurological indications—poses a significant risk, as any delays in approvals or unfavorable trial data could derail the company’s revenue timeline and shake investor confidence.
Trofinetide’s potential first-mover advantage in Rett syndrome offers a pathway to regulatory approval and commercial success, creating a strong, near-term revenue stream if upcoming data and launches proceed favorably.

Revenue & Expenses Breakdown
Neuren Pharmaceuticals Ltd
Balance Sheet Decomposition
Neuren Pharmaceuticals Ltd
Current Assets | 399.3m |
Cash & Short-Term Investments | 222.2m |
Receivables | 175.7m |
Other Current Assets | 1.4m |
Non-Current Assets | 10.4m |
PP&E | 31k |
Other Non-Current Assets | 10.3m |
Free Cash Flow Analysis
Neuren Pharmaceuticals Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Neuren Pharmaceuticals Ltd
Revenue
|
224.3m
AUD
|
Operating Expenses
|
-37.7m
AUD
|
Operating Income
|
186.6m
AUD
|
Other Expenses
|
-44.5m
AUD
|
Net Income
|
142m
AUD
|
NEU Profitability Score
Profitability Due Diligence
Neuren Pharmaceuticals Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.

Score
Neuren Pharmaceuticals Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
NEU Solvency Score
Solvency Due Diligence
Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NEU Price Targets Summary
Neuren Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
NEU
is 26.22 AUD
with a low forecast of 20.2 AUD and a high forecast of 32.34 AUD.
Dividends
Current shareholder yield for NEU is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
NEU
stock under the Base Case scenario is
6.63
AUD.
Compared to the current market price of 10.53 AUD,
Neuren Pharmaceuticals Ltd
is
Overvalued by 37%.